Premium
House dust mite sublingual immunotherapy: a double‐blind, placebo‐controlled study in elderly patients with allergic rhinitis
Author(s) -
Bozek A.,
Ignasiak B.,
Filipowska B.,
Jarzab J.
Publication year - 2013
Publication title -
clinical and experimental allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.462
H-Index - 154
eISSN - 1365-2222
pISSN - 0954-7894
DOI - 10.1111/cea.12039
Subject(s) - medicine , placebo , slit , allergy , house dust mite , sublingual immunotherapy , adverse effect , allergen , randomized controlled trial , population , sublingual administration , placebo controlled study , nose , surgery , immunology , double blind , biology , genetics , alternative medicine , environmental health , pathology
Summary Background Immunotherapy in elderly patients is controversial, and there is still no evidence supporting this treatment's safety and efficacy in this population. This study was performed to evaluate the safety and efficacy of specific sublingual immunotherapy for house dust mite ( HDM ) allergens in patients over 60 years of age with allergic rhinitis and a confirmed allergy to HDM . Objective This study sought to assess nasal symptoms during HDM season, reduce medication use and monitor for adverse reactions during immunotherapy. Methods One hundred and eleven 60‐ to 75‐year‐old patients with allergic rhinitis and a confirmed D ermatophagoides pteronyssinus and D ermatophagoides farinae allergy were included in the study. The patients were individually randomized to active or placebo groups using a double‐blind method ( NCTO 01605760 ClinicalTrials.gov). A total of 51 subjects in the sublingual allergen‐specific immunotherapy ( SLIT ) group ( S taloral 300 R , S tallergenes, F rance) and 57 subjects in the placebo group were monitored for 3 years. Results Forty‐seven patients completed 3 years of SLIT , and 48 subjects finished the placebo treatment in the same time period. The total nasal symptom score decreased by 44% in the active group and 6% in the placebo group after 3 years of SLIT . This difference was only significant in the active group ( P < 0.05). At the end of therapy, the total medication score of the active group decreased significantly by a maximum of 51% ( P < 0.05), whereas the total medication score of the placebo control group showed an insignificant decrease ( P = 0.56). There were no systemic adverse reactions during the study. Conclusions & Clinical Relevance Sublingual allergen‐specific immunotherapy in elderly patients with a HDM allergy to D . pteronyssinus and D . farinae generated a significant clinical improvement in the active group compared with the placebo group, particularly during the heating season. This therapy was well tolerated.